SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy’s launches generic version of Allegra-D 12 Hour in US

21 Nov 2014 Evaluate
Dr. Reddy’s Laboratories has launched its over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg / 120 mg, a bioequivalent generic version of Allegra-D 12 Hour Allergy & Congestion, in the US market on November 18, 2014. Dr. Reddy’s ANDA is approved by the United States Food & Drug Administration (USFDA).

The Allegra-D 12 Hour brand has US sales of approximately $49.8 million for the latest 52 weeks ending October 6, 2014 for total US Multi Outlet according to IRI. Dr. Reddy’s Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg / 120 mg is available in a 20 count blister.

Dr. Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Labs. Share Price

1269.80 -78.90 (-5.85%)
09-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1938.85
Dr. Reddys Labs. 1269.80
Cipla 1441.70
Zydus Lifesciences 1159.85
Lupin 2502.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: